Psc Associated Inflammatory Bowel Disease: A Distinct Entity Publisher Pubmed



Beheshtimaal A^{1, 2} ; Tamimi A² ; Iravani S³ ; Memarnejadian A⁴ ; Sorouri M⁵ ; Aghdaei HA¹ ; Zali MR¹ ; Hossein Khannazer N¹ ; Vosough M² Show Affiliations
Source: Expert Review of Gastroenterology and Hepatology Published:2022

Abstract

Introduction: Primary sclerosing cholangitis (PSC) is a rare, chronic, and progressive cholestatic disease involving intra- and/or extrahepatic bile ducts. PSC in many patients results in end-stage liver diseases. Nearly 60% of the PSC patients suffer from concomitant inflammatory bowel diseases (IBDs). Classically, IBDs are divided into two principle types: Crohn’s disease (CD) and ulcerative colitis (UC). However, with growing knowledge, PSC-associated IBD (PSC-IBD) seems to be a rather distinct entity with specific genetics, clinical, and microbiota characteristics. Areas covered: In this article, we aim to review the unique characteristics of PSC-IBD from clinical, genetic, and microbiota point of view. Expert opinion: PSC-IBD’s unique characteristics contribute to the notion that it could be a distinct entity. Acknowledgment of PSC-IBD as a novel entity necessitates designing new clinical guidelines for diagnosis and developing novel therapies. © 2022 Informa UK Limited, trading as Taylor & Francis Group.